Federal Register: November 26, 2008 (Volume 73, Number 229)

DOCID: fr26no08-85 FR Doc E8-28169

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Docket ID: [Docket No. FDA-2008-N-0038]

NOTICE: NOTICES

DOCID: fr26no08-85

DOCUMENT ACTION: Notice of public workshop.

SUBJECT CATEGORY:

Sex Differences in the Cardiovascular Device Trials; Public Workshop

DATES: The workshop will be held on December 9, 2008, from 9 a.m. to 5 p.m. Participants are encouraged to arrive early to ensure time for parking and security screening before the meeting. Security screening will begin at 8 a.m. and reception will begin at 8:30 a.m. Please register by December 2, 2008, using the instructions in this document. NonU.S. citizens are subject to additional security screening and should register as soon as possible.

DOCUMENT SUMMARY:

The Food and Drug Administration (FDA) is announcing a public workshop entitled ``Sex Differences in the Cardiovascular Device Trials.'' FDA is cosponsoring the conference with the Advanced Medical Technology Association (AdvaMed). The purpose of the workshop is to facilitate discussion between FDA and other interested parties on the study and analysis of sex and gender differences in cardiovascular medical device trials, in anticipation of issuance of draft guidance on this subject.

SUMMARY:

Sex Differences in the Cardiovascular Device Trials; Public Workshop,

SUPPLEMENTAL INFORMATION

I. Why Are We Holding This Public Workshop?

The purpose of the public workshop is to facilitate discussion between FDA and other interested parties on the study and analysis of sex and gender differences in cardiovascular medical device trials, in anticipation of issuance of draft guidance on this subject. II. What Are the Topics We Intend to Address at the Public Workshop?

We hope to discuss a large number of issues at the public workshop, including, but not limited to:

  • Current FDA perspective on sex/gender differences in pharmaceutical and medical device evaluation.
  • Medical device development in the U.S. regulatory environment.
  • Sex/genderspecific considerations in product design and clinical study design.
  • The current state of cardiovascular treatment for women.
  • Referral biases for women at risk for cardiovascular disease.
  • The Clinical Research Organization and Institutional Review Board perspectives on inclusion, exclusion, recruitment, and retention issues related to women in clinical trials.
  • The investigator/clinician perspective on the impact of sex/genderspecific issues on study design and conduct and available treatment options and limitations of use in women.
  • The female patient perspective on enrollment and participation in clinical trials.
  • The biostatistician perspective on statistical approaches and subgroup analysis in significant subpopulations.
  • Case studies on genderspecific trials.
    III. Is There a Fee and How Do I Register for the Public Workshop?

    There is a modest fee to attend the conference to defray the costs of meals provided and other expenses. The fee for the meeting for registrants from industry is $125.00, and the fee for government registrants is $75.00. Fees will be waived for invited speakers and panelists. The registration process will be handled by AdvaMed, which has extensive experience in planning, executing, and organizing educational meetings. Register online at http://www.AdvaMed.org. Although the
    [[Page 72064]]
    facility is spacious, registration will be on a firstcome, first served basis. NonU.S. citizens are subject to additional security screening, and should register as soon as possible.

    If you need special accommodations because of a disability, please contact Kathryn O'Callaghan at least 7 days before the public workshop. IV. Where Can I Find Out More About This Public Workshop?

    Background information on the public workshop, registration information, the agenda, information about lodging, and other relevant information will be posted, as it becomes available, on the Internet at http://www.fda.gov/cdrh/dsma/workshop.html.

    Dated: November 19, 2008.
    Jeffrey Shuren,
    Associate Commissioner for Policy and Planning.
    [FR Doc. E828169 Filed 112508; 8:45 am]
    BILLING CODE 416001S

    FOR FURTHER INFORMATION CONTACT

    Kathryn O'Callaghan, Center for Devices and Radiological Health (HFZ450), Food and Drug
    Administration, 9200 Corporate Blvd., rm. 230D, 2402764182, Rockville, MD 20850, kathryn.ocallaghan@fda.hhs.gov; or

    Ashley Boam, Center for Devices and Radiological Health (HFZ450), Food and Drug Administration, 9200 Corporate Blvd., rm. 230J, 240276 4188, Rockville, MD 20850, ashley.boam@fda.hhs.gov.